BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tesileanu CMS, Vallentgoed WR, Sanson M, Taal W, Clement PM, Wick W, Brandes AA, Baurain JF, Chinot OL, Wheeler H, Gill S, Griffin M, Rogers L, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, de Vos F, Mulholland PJ, Taphoorn MJB, de Heer I, Hoogstrate Y, de Wit M, Boggiani L, Venneker S, Oosting J, Bovée JVMG, Erridge S, Vogelbaum MA, Nowak AK, Mason WP, Kros JM, Wesseling P, Aldape K, Jenkins RB, Dubbink HJ, Baumert B, Golfinopoulos V, Gorlia T, van den Bent M, French PJ. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol 2021;141:945-57. [PMID: 33740099 DOI: 10.1007/s00401-021-02291-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Pellerino A, Caccese M, Padovan M, Cerretti G, Lombardi G. Epidemiology, risk factors, and prognostic factors of gliomas. Clin Transl Imaging. [DOI: 10.1007/s40336-022-00489-6] [Reference Citation Analysis]
2 Natsumeda M, Igarashi H, Gabdulkhaev R, Takahashi H, Motohashi K, Ogura R, Watanabe J, Tsukamoto Y, Okamoto K, Kakita A, Nakada T, Fujii Y. Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of "False-Positive" Cases. Diagnostics (Basel) 2021;11:2129. [PMID: 34829476 DOI: 10.3390/diagnostics11112129] [Reference Citation Analysis]
3 Franceschi E, Biase D, Di Nunno V, Pession A, Tosoni A, Gatto L, Lodi R, Tallini G, Visani M, Bartolini S, Brandes AA. IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. Pathol Res Pract 2021;221:153445. [PMID: 33887545 DOI: 10.1016/j.prp.2021.153445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Vallée A, Lecarpentier Y, Vallée JN. Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification. Biomedicines 2021;9:619. [PMID: 34070746 DOI: 10.3390/biomedicines9060619] [Reference Citation Analysis]
5 de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro Oncol 2022:noac139. [PMID: 35639513 DOI: 10.1093/neuonc/noac139] [Reference Citation Analysis]
6 Soldatelli JS, Oliveira IM, Kneubil MC, Henriques JAP. Gliomas molecular markers: importance in treatment, prognosis and applicability in brazilian health system. An Acad Bras Cienc 2022;94:e20211075. [PMID: 35766600 DOI: 10.1590/0001-3765202220211075] [Reference Citation Analysis]
7 Murnyak B, Huang LE. Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma. Cells 2021;10:2116. [PMID: 34440884 DOI: 10.3390/cells10082116] [Reference Citation Analysis]
8 Ahangari N, Munoz DG, Coulombe J, Gray DA, Engle EC, Cheng L, Woulfe J. Nuclear IMPDH Filaments in Human Gliomas. J Neuropathol Exp Neurol 2021;80:944-54. [PMID: 34498062 DOI: 10.1093/jnen/nlab090] [Reference Citation Analysis]
9 Di Nunno V, Franceschi E, Tosoni A, Gatto L, Maggio I, Lodi R, Angelini D, Bartolini S, Brandes AA. Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. Adv Ther 2022;39:165-77. [PMID: 34853984 DOI: 10.1007/s12325-021-01977-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tirrò E, Massimino M, Broggi G, Romano C, Minasi S, Gianno F, Antonelli M, Motta G, Certo F, Altieri R, Manzella L, Caltabiano R, Barbagallo GMV, Buttarelli FR, Magro G, Giangaspero F, Vigneri P. A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications. Front Oncol 2022;12:861078. [DOI: 10.3389/fonc.2022.861078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]